GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Cyclically Adjusted FCF per Share

Hepion Pharmaceuticals (FRA:336) Cyclically Adjusted FCF per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals Cyclically Adjusted FCF per Share?

Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Hepion Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.867. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-26), Hepion Pharmaceuticals's current stock price is €9.20. Hepion Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.00. Hepion Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Hepion Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Hepion Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Hepion Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hepion Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2,281.46 -4,829.93 - -

Competitive Comparison of Hepion Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Hepion Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hepion Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Hepion Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hepion Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.867/131.7762*131.7762
=-0.867

Current CPI (Mar. 2024) = 131.7762.

Hepion Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -254.500 100.560 -333.504
201409 -403.000 100.428 -528.796
201412 -581.000 99.070 -772.809
201503 -1,335.500 99.621 -1,766.565
201506 -1,933.000 100.684 -2,529.932
201509 -1,250.000 100.392 -1,640.779
201512 -2,517.500 99.792 -3,324.367
201603 -1,740.500 100.470 -2,282.826
201606 -1,304.000 101.688 -1,689.836
201609 -1,300.333 101.861 -1,682.223
201612 -1,012.400 101.863 -1,309.706
201703 -811.167 102.862 -1,039.182
201706 -630.667 103.349 -804.138
201709 -644.000 104.136 -814.936
201712 -342.286 104.011 -433.657
201803 -416.143 105.290 -520.828
201806 -365.625 106.317 -453.180
201809 -303.700 106.507 -375.755
201812 -373.000 105.998 -463.712
201903 -142.692 107.251 -175.322
201906 -26.163 108.070 -31.902
201909 -9.462 108.329 -11.510
201912 -11.707 108.420 -14.229
202003 -19.512 108.902 -23.610
202006 -6.501 108.767 -7.876
202009 -7.248 109.815 -8.697
202012 -2.324 109.897 -2.787
202103 -2.393 111.754 -2.822
202106 -1.129 114.631 -1.298
202109 -2.534 115.734 -2.885
202112 -1.712 117.630 -1.918
202203 -2.413 121.301 -2.621
202206 -1.862 125.017 -1.963
202209 -3.322 125.227 -3.496
202212 -1.188 125.222 -1.250
202303 -2.013 127.348 -2.083
202306 -2.999 128.729 -3.070
202309 -2.743 129.860 -2.783
202312 -2.151 129.419 -2.190
202403 -0.867 131.776 -0.867

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Hepion Pharmaceuticals  (FRA:336) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Hepion Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (FRA:336) Business Description

Traded in Other Exchanges
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines